X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 53 filers reported holding X4 PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,706,000 | +77.3% | 997,719 | 0.0% | 0.53% | +109.5% |
| Q2 2022 | $962,000 | -44.9% | 997,719 | 0.0% | 0.25% | -40.9% |
| Q1 2022 | $1,746,000 | -47.9% | 997,719 | -31.9% | 0.43% | -58.1% |
| Q4 2021 | $3,353,000 | -61.9% | 1,464,099 | -12.0% | 1.02% | -44.8% |
| Q3 2021 | $8,805,000 | -5.9% | 1,664,540 | +15.7% | 1.85% | +10.0% |
| Q2 2021 | $9,353,000 | – | 1,438,899 | – | 1.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |